Revolutionizing Multiple Myeloma Treatment Through Advanced Imaging and Innovative Therapies

Hematologic cancers, originating from lymphoid and myeloid cell lines, represent about 10% of newly diagnosed malignant tumors in the United States. Among these, Multiple Myeloma survival has improved over the last decade, with the emergence of cutting-edge therapies like CAR T-cell treatments and bispecific antibodies. These innovative approaches, when aligned with new imaging technologies, offer improved avenues for patients by enhancing treatment efficacy while managing potential risks associated with traditional therapies.

In the evolving field of multiple myeloma (MM) treatment, the integration of lab data, medical imaging and clinical data in a Blinded Independent Central Review (BICR) setting plays a crucial role. This approach ensures unbiased evaluation of treatment responses, helping clinicians make informed decisions based on standardized assessments and objective, quantitative criteria. Guidelines by the International Myeloma Working Group (IMWG) list all three major imaging techniques i.e. CT, FDG-PET/CT, and MRI for various aspects of myeloma clinical trials evaluation. CT and PET/CT offer superior sensitivity in detecting osteolytic lesions and disease progression compared to conventional radiographs, while WB-MRI is considered highly sensitive for detecting and staging myeloma.

Different imaging modalities offer unique advantages:

• CT provides detailed 3D information, particularly useful in detecting non-lytic medullary lesions and assessing complications like pathologic fractures.
• Dual-energy CT enhances detection of bone marrow infiltration in MM, showing promise in improving sensitivity over conventional CT.
• Whole Body MRI (WBMRI) with DWI is highly sensitive for bone marrow imaging, providing detailed insights into disease involvement and treatment response evaluation.
• PET/CT combines functional and morphologic information, aiding in diagnosis, prognostication, treatment response assessment, and detecting minimal residual disease (MRD), offering added value to bone marrow examinations.
• Novel tracers like 11C-methionine and 68Ga-pentixafor are showing promise in enhancing specificity for myeloma detection.

As we continue to leverage advanced therapies and data-driven decision-making processes, we pave the way for improved clinical trial reads, patient care and outcomes in the fight against multiple myeloma. Imaging Endpoints, with a perfect inspection record and industry-leading marketing authorization success rate, understands the critical and unique nature of hematologic cancer clinical trials and works with you to optimize the imaging and clinical data assessment.

To start a conversation with our physicians and operations specialists for your hematologic cancer clinical trials